论文部分内容阅读
目的比较替吉奥联合紫杉醇方案与传统FOLFOX方案(奥沙利铂+氟尿嘧啶+亚叶酸钙)治疗晚期胃癌的疗效和安全性。方法选取福建医科大学省立临床医学院福建省立医院62例晚期胃癌患者,随机分为观察组34例和对照组28例。观察组行替吉奥联合紫杉醇方案化疗,对照组行FOLFOX方案(奥沙利铂+氟尿嘧啶+亚叶酸钙)化疗,化疗期间定期监测血常规、肝肾功能,2个周期后进行疗效评价,即病灶最大径总和变化。结果观察组有效率55.88%,疾病控制率为91.18%,均优于对照组,两组比较差异均无统计学意义(χ~2=0.21、1.97,P>0.05)。两组不良反应为轻度的骨髓抑制、消化道反应等,均可耐受。结论替吉奥联合紫杉醇和传统FOLFOX方案两组治疗方案均可用于晚期胃癌,疗效相当,不良反应发生症状轻,患者可耐受。
Objective To compare the efficacy and safety of tegaserod in combination with paclitaxel and traditional FOLFOX regimen (oxaliplatin + fluorouracil + leucovorin) in the treatment of advanced gastric cancer. Methods Sixty-two patients with advanced gastric cancer from Fujian Provincial Hospital of Fujian Medical University and Fujian Provincial Hospital were randomly divided into observation group (34 cases) and control group (28 cases). Patients in the observation group were treated with chemotherapy combined with ticagrelor plus paclitaxel, while those in the control group were treated with FOLFOX (oxaliplatin + fluorouracil + leucovorin) chemotherapy. Blood chemistry, liver and kidney function were regularly monitored during chemotherapy. Efficacy was evaluated after 2 cycles The maximum diameter of the lesion changes. Results The observation group had an effective rate of 55.88% and disease control rate of 91.18%, both of which were superior to the control group. There was no significant difference between the two groups (χ ~ 2 = 0.21, 1.97, P> 0.05). Two groups of adverse reactions to mild myelosuppression, gastrointestinal reactions, can be tolerated. Conclusion Both the treatment of tegaserod combined with paclitaxel and the traditional FOLFOX regimen can be used for advanced gastric cancer with comparable curative effect and mild adverse reactions. Patients are tolerant.